TLDR
- ARK Invest sold 84,392 shares of Alphabet worth $28.6 million on September 9, 2026
- ARK bought 43,091 shares of Meta Platforms for $26.4 million after Meta launched its new AI agent, Muse
- Meta stock jumped 6.55% on the day; Alphabet fell 2.28%
- ARK also bought shares in three biotech companies: Beam Therapeutics, CRISPR Therapeutics, and Intellia Therapeutics
- ARK trimmed its position in Tempus AI, selling around $1.5 million worth of shares
Cathie Wood’s ARK Invest made several large trades on Wednesday, September 9, 2026. The firm sold 84,392 shares of Alphabet worth about $28.6 million across its ARKK and ARKW funds.
At the same time, ARK bought 43,091 shares of Meta Platforms for roughly $26.4 million. Meta stock rose 6.55% that day after the company unveiled Muse, a new AI agent built to handle tasks like shopping, travel bookings, and emails.
Meta CEO Mark Zuckerberg has described the product as part of a push toward what he calls “personal superintelligence.” The launch gave investors a concrete example of how Meta plans to use its AI spending.
Meta expects to spend between $130 billion and $145 billion this year, with a large portion going toward AI development.
Alphabet shares fell 2.28% on the same day. Mizuho analyst Lloyd Walmsley said Meta’s Muse launch could renew concerns about Google’s Gemini AI models and the effect of AI agents on traditional search.
ARK has been reducing its Alphabet position over several weeks. Wednesday’s sale continues that trend rather than being a single sudden move.
ARK Adds to Biotech Positions
ARK also added to several biotech holdings during the session. The firm bought 271,159 shares of Beam Therapeutics for about $7.3 million. Beam shares fell 6.17% to $25.18 after the company released updated data from a Phase 1/2 trial of BEAM-302, a treatment for alpha-1 antitrypsin deficiency.
ARK bought 47,113 shares of CRISPR Therapeutics for around $2.6 million. CRISPR shares dropped 2.43% to $53.45 on the day.
The firm also picked up 204,206 shares of Intellia Therapeutics for approximately $2.6 million. Intellia shares fell 4.16% to $12.21.
The FDA recently accepted Intellia’s application for lonvo-z with Priority Review. A decision is expected by March 10, 2027. If approved, lonvo-z could be the first one-time treatment for hereditary angioedema using in vivo CRISPR gene editing.
On the sell side, ARK reduced its stake in Tempus AI by 22,767 shares, valued at about $1.5 million. Tempus shares fell 4.68% during the session. ARK has been selling Tempus shares across several recent trading days.
ARK’s trades on September 9 show the firm shifting weight from Alphabet toward Meta and biotech names, buying into price dips while trimming positions that have seen recent declines.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
